Form 4: Baker Bros. Funds Boost Denali Therapeutics Stake

Baker Bros. Advisors' affiliated funds acquired over 2.2 million prefunded warrants in Denali Therapeutics through a public offering.

Summary

• 667, L.P. purchased 190,523 prefunded warrants to acquire common stock of Denali Therapeutics Inc.
• Baker Brothers Life Sciences, L.P. purchased 2,095,191 prefunded warrants to acquire common stock of Denali Therapeutics Inc.
• These warrants have an exercise price of $0.01 per share and no expiration date.
• The prefunded warrants were acquired for $17.49 per share in a public offering that closed on December 11, 2025.
• Following these transactions, 667, L.P. beneficially owns 2,335,469 prefunded warrants.
• Following these transactions, Baker Brothers Life Sciences, L.P. beneficially owns 25,996,310 prefunded warrants.
• The warrants are exercisable on a 1-for-1 basis into Common Stock, subject to a beneficial ownership limitation of 4.99% of outstanding shares, which can be increased to 19.99% with a 61-day notice to the Issuer.
• Julian C. Baker and Felix J. Baker, along with their affiliated entities, disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein.

Sentiment

Score: 8

Explanation: The substantial investment by a sophisticated, insider investor like Baker Bros. Advisors and its affiliates, through the purchase of prefunded warrants in a public offering, indicates strong confidence in Denali Therapeutics' future prospects. This is generally viewed as a highly positive signal for the company's stock.

Positives

• A significant investment by Baker Bros. Advisors' affiliated funds, which are sophisticated institutional investors, indicates strong confidence in Denali Therapeutics' future prospects.
• The acquisition of prefunded warrants at $17.49 per share suggests a belief in the potential for future stock appreciation above this price.

Risks

• The value of the prefunded warrants is directly tied to the future performance of Denali Therapeutics' common stock, exposing the investment to market fluctuations.
• Beneficial ownership limitations (initially 4.99%, adjustable to 19.99%) may restrict the immediate full conversion of warrants into common stock, potentially impacting liquidity or control.

Future Outlook

The significant investment by Baker Bros. affiliated funds suggests a positive long-term outlook on Denali Therapeutics' future prospects and potential for stock appreciation, particularly given their expertise in the biotechnology sector.

Management Comments

• Julian C. Baker and Felix J. Baker, along with their affiliated entities, disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein.

Industry Context

Baker Bros. Advisors is a well-known specialist investor in the biotechnology sector. Their substantial investment in Denali Therapeutics, a company focused on neurodegenerative diseases, signals continued confidence in the biotech industry's innovation and the specific therapeutic area Denali addresses.

Comparison to Industry Standards

• This Form 4 details a specific insider transaction rather than company performance metrics, making direct comparison to industry-wide financial standards or competitor results not applicable.

Related Party Transactions

• Baker Bros. Advisors LP, an investment adviser to the purchasing funds, and its managing members Julian C. Baker and Felix J. Baker, who are also directors (or deemed directors by deputization) of Denali Therapeutics Inc., are involved in this transaction.
• Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities held directly by the Funds due to their ownership interests and rights to receive a portion of the profits.

Stakeholder Impact

• Shareholders: The significant insider investment could be perceived as a positive signal, potentially boosting investor confidence. However, future exercise of warrants could lead to dilution.
• Company: The public offering provided capital to Denali Therapeutics Inc.

Next Steps

• The reporting persons may choose to exercise the prefunded warrants into common stock at any time, subject to beneficial ownership limitations.

Key Dates

Recommendation

The significant investment by Baker Bros. Advisors, a highly respected and specialized biotech investor with deep industry knowledge and a board presence, signals strong conviction in Denali Therapeutics' long-term value proposition. The purchase of prefunded warrants at $17.49 per share, with a nominal exercise price, suggests an expectation of substantial future stock appreciation. This insider buying activity, especially from a 10% owner, is a powerful positive indicator for potential investors.

Keywords

Denali Therapeutics, DNLI, Baker Bros. Advisors, Form 4, insider trading, prefunded warrants, beneficial ownership, public offering, biotechnology investment